(MENAFN- Straits Research)
Cancer Microbiome Sequencing Market Size Analysis
The global cancer microbiome sequencing market size was valued at USD 384.25 million in 2025 and is projected to grow from USD 460.79 million in 2026 to USD 1970.78 million by 2034, registering a CAGR of 19.92% during the forecast period from 2026 to 2034. North America dominated the cancer microbiome sequencing market with a market share of 42.6% in 2025.
Cancer microbiome sequencing involves analyzing the genetic material of microorganisms found in or around tumors to understand their role in cancer development, progression, and treatment response. It uses advanced sequencing technologies to identify and characterize bacteria, fungi, viruses, and other microbes associated with cancer.
Cancer Microbiome Sequencing Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 384.25 Million
2026 Market Size: USD 460.79 Million
2034 Projected Market Size: USD 1970.78 Million
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 19.92%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.6%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 21.65%
Segment Insights
By Offering
Leading Segment: Product
Market Share in 2025: 64.7%
By Application
Fastest-Growing Segment: Translational Research and Diagnostics
CAGR: 18.45% (2026–2034)
By Technology
Leading Segment: Next-Generation Sequencing
Market Share in 2025: 72.8%
By End-User
Fastest-Growing Segment: Pharmaceutical and Biotechnology Companies
CAGR: 19.65% (2026–2034)
Download a Free Sample To learn more about this report,
Cancer Microbiome Sequencing Market Trends
Growing Shift Toward High-Resolution Shotgun Metagenomic Sequencing
The cancer microbiome sequencing market is increasingly moving beyond basic 16S rRNA profiling toward shotgun metagenomic sequencing that can characterize microbial communities at species and strain levels while also identifying functional genes and metabolic pathways. High-resolution metagenomics is therefore becoming an important part of cancer microbiome sequencing market trends.
In September 2025, PacBio selected 4 projects for its 2025 Microbiome SMRT Grant program from hundreds of proposals. One project specifically applies HiFi shotgun metagenomic sequencing to fecal samples from patients with colorectal adenomas to reconstruct metagenome-assembled genomes and investigate microbial involvement in progression toward colorectal cancer.
Increasing Integration of Long-Read Sequencing Into Oncology Workflows
Cancer microbiome studies increasingly require sequencing technologies capable of resolving complex microbial genomes, structural variation, and mixed biological signals alongside tumor-related molecular information. Long-read sequencing can provide more complete genomic assemblies and improve identification of microbial organisms that are difficult to characterize using fragmented short reads. Integration with established oncology enrichment and analysis workflows is consequently expanding the cancer microbiome sequencing industry toward more comprehensive translational research.
In May 2026, Oxford Nanopore Technologies expanded its compatible sequencing ecosystem across oncology, pathogen, and multi-omics workflows. The program added compatibility with Agilent SureSelect targeted enrichment while extending real-time, any-length sequencing across 3 major areas-oncology, pathogen research, and multi-omics.
Cancer Microbiome Sequencing Market Dynamics
Market Driver
Growing Evidence Linking the Microbiome With Cancer Development
Researchers are identifying microbial communities within tumors and the gastrointestinal tract that may. This is increasing the need to sequence bacteria, fungi, viruses, and other microorganisms alongside host and tumor information. As microbiome signatures become more closely associated with different cancer types, laboratories require increasingly sophisticated sequencing and computational workflows. Expanding evidence around tumor-microbe interactions is therefore strengthening cancer microbiome sequencing market demand.
In March 2025, the National Cancer Institute-supported project on microbiome-mediated tumor immunomodulation entered its R33 research phase. The project runs from March 2025 through February 2028 and investigates microbiome interactions with immune-checkpoint pathways in colorectal cancer, including tumors that respond poorly to checkpoint immunotherapy.
Market Restraint
High Host-DNA Content Increases Useful Sequencing Costs
Tumor tissue, blood, and other human specimens can contain overwhelmingly more host DNA than microbial DNA. When samples are sequenced without effective host depletion, a large proportion of reads may represent human genetic material rather than microorganisms, requiring substantially deeper sequencing to obtain sufficient microbial information. This increases reagent, sequencing, storage, and bioinformatics costs. Low microbial abundance can consequently restrain cancer microbiome sequencing market growth by making high-quality tumor microbiome studies expensive.
In June 2025, QIAGEN presented an optimized host-DNA depletion workflow for tissue, swab, and bodily-fluid microbiome samples. The company highlighted that microbial DNA can represent only a very small fraction of total sample DNA and demonstrated depletion approaches designed to reduce human DNA to negligible levels before metagenomic NGS.
Market Opportunity
Expansion of Microbiome Sequencing for Colorectal Cancer Detection
Colorectal cancer offers a significant opportunity because stool samples provide non-invasive access to microbial communities associated with the gastrointestinal tract. Sequencing these communities can potentially identify combinations of microbial species and functional signatures associated with precancerous lesions or cancer. Microbiome-based screening could complement existing stool and colonoscopy approaches while supporting more personalized risk assessment. Non-invasive colorectal screening can therefore help specialized providers increase cancer microbiome sequencing market share.
In January 2025, Shoreline Biome received an NIH Phase I SBIR award of USD 405,973 to develop a high-throughput colorectal cancer screening platform using its Titan-1 technology for non-invasive fecal microbiome profiling with at-home sample collection.
Market Challenge
Interpreting Complex Multi-Kingdom Microbial Signals
Cancer-associated microbiomes can contain bacteria, fungi, viruses, archaea, and other microorganisms whose abundance may vary substantially between patients, tumor types, anatomical sites, treatments, and populations. Detecting microbial DNA alone does not establish whether an organism contributes to cancer, responds to the tumor environment, or represents contamination. Researchers therefore need large datasets and advanced bioinformatics to distinguish meaningful biological signals from background variation. Reliable interpretation remains a major challenge as cancer microbiome sequencing market size expands toward translational applications.
In January 2026, the European Research Council-supported NEXT-CRC project began a 5-year research program focused on next-generation colorectal cancer microecosystems and microbiome-driven immunotherapies. The project has a total budget of approximately EUR 1.50 million and runs through December 2030, highlighting the scale of research required to understand complex tumor-microbiome interactions.
Cancer Microbiome Sequencing Market Segmentation Analysis
By Offering
Product Segment Dominated the Market with 64.7% Share in 2025
The product segment dominated the global cancer microbiome sequencing market with a 64.7% market share in 2025, valued at USD 0.25 billion. Its leadership is supported by the growing use of sequencing kits, assays, software, and other laboratory products required to characterize microbial communities associated with cancer research. Increasing adoption of sequencing-based approaches in microbiome studies is encouraging researchers to use integrated product portfolios for sample preparation, sequencing, analysis, and interpretation.
Service offerings continue to support laboratories and research organizations that require specialized sequencing, bioinformatics, data analysis, and workflow support. As microbiome studies become more complex, demand for external expertise and scalable sequencing services is expanding across research and clinical-development environments.
Request Customization to receive a tailored report.
By Application
Translational Research and Diagnostics Segment Dominated the Market with 100% Share in 2025
The translational research and diagnostics segment accounted for a 100% share of the global cancer microbiome sequencing market in 2025, valued at USD 0.38 billion. Within this broader application area, colorectal cancer represents the largest specific cancer-type segment. Growing research into interactions between microbial communities, tumor biology, immune responses, and treatment outcomes is supporting the use of microbiome sequencing in cancer-related research and diagnostic development.
Colorectal, cervical, oral, and other cancer types continue to represent important areas of investigation. Researchers are examining how microbiome profiles may contribute to disease understanding, biomarker discovery, treatment response assessment, and the development of more personalized approaches to cancer research.
By Technology
Next-Generation Sequencing Segment Dominated the Market with 72.8% Share in 2025
The next-generation sequencing segment dominated the global cancer microbiome sequencing market with a 72.8% market share in 2025, valued at USD 0.28 billion. NGS enables researchers to analyze microbial genetic material at scale, making it valuable for characterizing complex microbial communities associated with tumors and surrounding biological environments. Its ability to generate large volumes of sequencing data supports detailed microbiome profiling and comparative research.
Polymerase chain reaction remains an important technology for targeted microbial detection and validation. Within NGS, sequencing by synthesis, sequencing by ligation, and other approaches continue to address different research requirements based on workflow design, sequencing performance, and analytical objectives.
By End-User
Pharmaceutical and Biotechnology Companies Segment is Projected to Register the Fastest Growth at a CAGR of 19.65%
The pharmaceutical and biotechnology companies segment is projected to register the fastest growth at a CAGR of 19.65% during the forecast period. Increasing interest in the microbiome's potential role in cancer biology is encouraging drug developers and biotechnology companies to investigate microbial biomarkers, therapeutic targets, treatment response, and microbiome-based interventions. Sequencing technologies provide researchers with tools to characterize microbial communities and generate data that can support drug-development programs.
Academic and research institutes remain important users of cancer microbiome sequencing for basic and translational studies. Hospitals and diagnostic laboratories are also exploring sequencing-based approaches as research progresses toward clinically relevant biomarkers, diagnostic applications, and more personalized cancer-management strategies.
Speak to an Analyst to discuss market opportunities.
Cancer Microbiome Sequencing Market Regional Outlook
North America Cancer Microbiome Sequencing Market Analysis
North America's cancer microbiome sequencing market accounted for 42.6% of the global market, reaching USD 0.16 billion in 2025, and is projected to grow at a CAGR of 17.85% during the forecast period.
United States Cancer Microbiome Sequencing Market Insights
The United States represents a major market in North America. Its advanced genomics and cancer research ecosystem, strong biotechnology sector, and increasing focus on precision oncology continue to support demand for cancer microbiome sequencing technologies.
Canada Cancer Microbiome Sequencing Market Insights
Canada's established biomedical research infrastructure, expanding genomics capabilities, and increasing research into the relationship between the microbiome and cancer continue to support market development.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Cancer Microbiome Sequencing Market Analysis
The Asia Pacific cancer microbiome sequencing market accounted for 19.8% of the global market, reaching USD 0.08 billion in 2025, and is projected to grow at a CAGR of 21.65% during the forecast period. The region records the fastest growth among the listed markets, supported by expanding genomic research capabilities, increasing cancer incidence, growing investments in biotechnology, and rising adoption of next-generation sequencing and precision medicine technologies.
China Cancer Microbiome Sequencing Market Insights
China represents a major market within the Asia Pacific. Expanding cancer research programs, growing genomics capabilities, increasing biotechnology investments, and rising adoption of sequencing technologies continue to drive market development.
Japan Cancer Microbiome Sequencing Market Insights
Japan's advanced healthcare and life sciences infrastructure, strong cancer research capabilities, and increasing focus on precision medicine and molecular diagnostics continue to support market growth.
India Cancer Microbiome Sequencing Market Insights
India's expanding biotechnology sector, increasing cancer research activities, growing genomics capabilities, and rising investments in advanced sequencing technologies continue to create opportunities for cancer microbiome sequencing market development.
Europe's Cancer Microbiome Sequencing Market Analysis
Europe's cancer microbiome sequencing market accounted for 27.4% of the global market, reaching USD 0.11 billion in 2025, and is expected to register a CAGR of 17.25% during the forecast period. Growing investments in cancer genomics, increasing research into tumor microbiomes, expanding precision medicine initiatives, and rising adoption of advanced sequencing technologies continue to support regional market growth.
Germany Cancer Microbiome Sequencing Market Insights
Germany represents a major European market. Its strong biomedical research infrastructure, expanding cancer genomics activities, and increasing investments in precision medicine continue to support cancer microbiome sequencing research and applications.
United Kingdom Cancer Microbiome Sequencing Market Insights
The United Kingdom's established genomics research ecosystem, growing cancer research activities, and increasing focus on personalized oncology continue to create opportunities for cancer microbiome sequencing technologies.
Latin America Cancer Microbiome Sequencing Market Analysis
Latin America's cancer microbiome sequencing market accounted for 6.1% of the global market, reaching USD 0.02 billion in 2025, and is expected to grow at a CAGR of 18.15% during the forecast period. Increasing cancer research, gradual expansion of genomic testing infrastructure, growing biotechnology activities, and rising awareness of precision medicine continue to support regional market growth.
Brazil Cancer Microbiome Sequencing Market Insights
Brazil represents a major regional market. Its expanding biomedical research sector, increasing cancer research activities, and growing adoption of genomic technologies continue to create opportunities for cancer microbiome sequencing.
Middle East & Africa Cancer Microbiome Sequencing Market Analysis
The Middle East & Africa cancer microbiome sequencing market accounted for 4.1% of the global market, reaching USD 0.02 billion in 2025, and is anticipated to grow at a CAGR of 16.95% during the forecast period. Increasing investments in healthcare and biotechnology, growing cancer research activities, and gradual development of genomic testing infrastructure continue to support regional market development.
UAE Cancer Microbiome Sequencing Market Insights
The UAE's investments in advanced healthcare, genomics, biotechnology, and precision medicine continue to support the adoption of advanced sequencing technologies for cancer research.
Saudi Arabia Cancer Microbiome Sequencing Market Insights
Saudi Arabia's expanding healthcare infrastructure, growing investments in genomics and biotechnology, and increasing focus on advanced cancer research continue to strengthen opportunities for cancer microbiome sequencing technologies.
Cancer Microbiome Sequencing Market Competitive Landscape
The global cancer microbiome sequencing market is highly competitive, with leading genomics, sequencing, molecular diagnostics, and microbiome technology companies competing through next-generation sequencing (NGS), metagenomic analysis, microbial profiling, bioinformatics, and precision oncology solutions. The major players in the market include Novogene Corporation, Psomagen, PerkinElmer Genomics, Illumina, Thermo Fisher Scientific, Viome, Invivo Diagnostics, Zymo Research Corp., Metabiomics, and others.
Industry participants are focusing on developing advanced sequencing and bioinformatics technologies for characterizing tumor-associated microbiota and identifying microbial signatures associated with cancer development, diagnosis, prognosis, and treatment response. Growing interest in precision oncology, biomarker discovery, immunotherapy response prediction, and non-invasive cancer diagnostics is also encouraging companies to expand microbiome sequencing capabilities and research collaborations.
Illumina: An Emerging Market Leader
Illumina is a leading genomics technology company providing next-generation sequencing platforms, consumables, and informatics solutions used extensively in cancer genomics and microbiome research. Its sequencing technologies enable researchers to analyze microbial communities and characterize genetic and molecular changes associated with cancer, supporting applications ranging from biomarker discovery to translational research.
In 2026, Illumina continued strengthening its sequencing and multi-omics ecosystem, with a focus on enabling higher-throughput and more comprehensive genomic analysis for research and clinical applications. These advancements reinforce Illumina's competitive position in the evolving global cancer microbiome sequencing market.
List of Key and Emerging Players in Cancer Microbiome Sequencing Market
Novogene Corporation
Psomagen
PerkinElmer Genomics
Illumina
Thermo Fisher Scientific
Viome
Invivo Diagnostics
Zymo Research Corp
Metabiomics.
Key Industry Developments
January 2026: Illumina launched Connected Multiomics, a cloud-based analysis and interpretation platform supporting integrated multiomic workflows. The software enables scalable analysis and visualization of complex biological datasets, including applications in oncology and microbiome-linked research.
January 2026: QIAGEN advanced three automated sample-preparation systems for 2026 launches, targeting high-throughput applications including microbiome research, liquid biopsy, and oncology workflows.
May 2025: MapmyGenome acquired Microbiome Insights, a Canadian microbial sequencing specialist with a CAP-accredited laboratory and microbiome-focused intellectual property. The acquisition expanded MapmyGenome's microbial sequencing and microbiome analysis capabilities and strengthened its international genomics operations.
Report Scope
Comments
No comment